The investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

The FDA has accepted the New Drug Application for doravirine/islatravir for adults with virologically-suppressed HIV-1 infection.

The global recombinant proteins market size was US$ 1.5 billion in 2021. The global recombinant proteins market is forecasted to grow to US$ 4 billion by 2030 by registering a compound annual growth ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...